Carlsmed, Inc.
Moat Score — Carlsmed, Inc.
Total Moat Score
12 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Carlsmed holds 48 issued patents and roughly 120 pending applications covering its personalized implants, manufacturing process, and AI algorithms, plus a proprietary dataset of about 4 million radiographic images and clinical outcomes data (COMPASS Registry) that is difficult for competitors to replicate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small, still-unprofitable company using contract manufacturers, Carlsmed has no scale cost advantage versus giants like Medtronic, Stryker, and Zimmer Biomet, which can produce stock implants far more cheaply. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Strong clinical evidence (a 74% relative reduction in two-year revision rate versus stock implants) supports premium pricing for personalized implants against commodity alternatives, though hospital purchasing committees and payers still constrain how much surgeons can pay. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | There is a modest data network effect — more surgeries feed more imaging and outcomes data back into the AI planning platform, improving future surgical plans — but this is an indirect, slow-building effect rather than a classic two-sided network effect. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once surgeons build workflow familiarity and trust in aprevo's planning process and outcomes data, switching back to stock implants involves both behavioral and clinical-comfort friction, though large device makers can and do compete for the same surgeon relationships. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | With an estimated ~4,000 addressable U.S. spine surgeons and a large ($19.4 billion) total addressable market, there is ample room for multiple personalized-implant competitors to enter and scale alongside Carlsmed. |